Lu Lab
Principal Investigator: Zheng-Rong Lu
Institution: Case Western Reserve University (Cleveland, OH)
Primary Subfield: Synthetic Bio
Recruitment Status: Inquire for rotation/fellowship opportunities
Research Focus
The ultimate goal of this project is to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). PDAC is recognized for its aggressive nature and notably poor long- term survival rates, presenting a pressing clinical need for effective curative therapies. While cancer immunotherapy has demonstrated the potential for disease-free outcomes, the efficacy of current clinical immunotherapies for PDAC is limited by the immunosuppressive tumor microenvironment. Our central hypothesis is that innovative nanosized therapeutic cancer vaccines, specifically targeting multiple mutant oncogenes in pancreatic ductal adenocarcinoma (PDAC), could potentially overcome tumor heterogeneity, thereby achieving a high rate of disease-free survival. Additionally, we believe that the synergistic combination of these nanovaccines with inhibitors targeting a potent immune checkpoint protein could markedly amplify antitumor immune responses and enhance overall therapeutic efficacy. To non- invasively assess the therapeutic impact of these nanovaccines, we will utilize cutting-edge magnetic resonan…
Active NIH Awards
- 5R01CA297621-02: Anticancer ELNP nanovaccines for curative treatmentof pancreatic cancer (2026)
- 5R01CA235152-08: Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy (2026)
- 5R01CA235152-07: Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy (2025)
- 1R01CA297621-01: Anticancer ELNP nanovaccines for curative treatmentof pancreatic cancer (2025)
- 2R01CA235152-06: Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy (2024)
Explore 700+ US Biology Labs on FindBioLabs.com